NOT-NS-19-052: Notice of Correction to Application Types Allowed for RFA-NS-19-017 "HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional)"

Notice of Correction to Application Types Allowed for RFA-NS-19-017 "HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional)"

Notice Number: NOT-NS-19-052

Key Dates
Release Date: April 10, 2019

Related Announcements
RFA-NS-19-017

Issued by
National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this notice is to inform potential applicants of a correction to Application Types Allowed in response to RFA-NS-19-017 "HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional)". Renewal Direct Phase II applications are allowed for this Funding Opportunity Announcement. This notice will be effective for the June 21, 2019 application due date and subsequent due dates.

The following section of RFA-NS-19-017 has been modified (shown in bold-italics below):

Currently Reads:

Section II. Award Information

Funding Instrument:

Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.

Application Types Allowed:

Revision
New (Fast-Track)
New (Phase II* SBIR Direct Phase II Only)
Renewal(Phase II* Direct Phase II not allowed)
Resubmission (all phases)

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.

Modified to Read:

Section II. Award Information

Funding Instrument:

Application Types Allowed:

Revision
New (Fast-Track)
New (Phase II* SBIR Direct Phase II Only)
Renewal (Phase II)
Resubmission (all phases)

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Nick Langhals, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email:nick.langhals@nih.gov